Immunotherapy for Prostate Cancer

E-ISSN： 1873-4286|12|7|807-817

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.12, Iss.7, 2006-03, pp. : 807-817

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A New Era of Immunotherapy in Prostate Cancer

Current Molecular Pharmacology, Vol. 9, Iss. 3, 2016-09 ,pp. : 217-225

Bentham Science Publishers

Access to resources Recommend Favorite

Prostate cancer immunotherapy at the dawn of the new millennium

By Salgaller M.L.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. : 1217-1229

Informa Healthcare

Access to resources Recommend Favorite

Combining low-dose cyclophosphamide with GM-CSF–secreting prostate cancer immunotherapy enhances antitumor immune effects

By Antonarakis Emmanuel S Carducci Michael A

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 311-314

Informa Healthcare

Access to resources Recommend Favorite

HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer

By Sonpavde Guru Wang Mingjun Peterson Leif Wang Helen Joe Teresa Mims Martha Kadmon Dov Ittmann Michael Wheeler Thomas Gee Adrian Wang Rong-Fu Hayes Teresa

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 235-242

Springer Publishing Company

Access to resources Recommend Favorite

Prostate Cancer

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 7, 2007-08 ,pp. : 650-650

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite